We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, Pacific Biosciences of California (PACB - Free Report) closed at $1.99, marking a -2.93% move from the previous day. This move lagged the S&P 500's daily loss of 1.11%. At the same time, the Dow lost 0.09%, and the tech-heavy Nasdaq lost 1.88%.
The maker of genetic analysis technology's stock has climbed by 52.99% in the past month, exceeding the Medical sector's loss of 0.4% and the S&P 500's gain of 2.06%.
Analysts and investors alike will be keeping a close eye on the performance of Pacific Biosciences of California in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$0.13, marking a 8.33% fall compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $37.86 million, down 1.51% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.43 per share and a revenue of $156.1 million, representing changes of +18.87% and -2.44%, respectively, from the prior year.
Any recent changes to analyst estimates for Pacific Biosciences of California should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Pacific Biosciences of California currently has a Zacks Rank of #3 (Hold).
The Medical - Instruments industry is part of the Medical sector. With its current Zacks Industry Rank of 94, this industry ranks in the top 39% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
In the latest trading session, Pacific Biosciences of California (PACB - Free Report) closed at $1.99, marking a -2.93% move from the previous day. This move lagged the S&P 500's daily loss of 1.11%. At the same time, the Dow lost 0.09%, and the tech-heavy Nasdaq lost 1.88%.
The maker of genetic analysis technology's stock has climbed by 52.99% in the past month, exceeding the Medical sector's loss of 0.4% and the S&P 500's gain of 2.06%.
Analysts and investors alike will be keeping a close eye on the performance of Pacific Biosciences of California in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$0.13, marking a 8.33% fall compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $37.86 million, down 1.51% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.43 per share and a revenue of $156.1 million, representing changes of +18.87% and -2.44%, respectively, from the prior year.
Any recent changes to analyst estimates for Pacific Biosciences of California should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Pacific Biosciences of California currently has a Zacks Rank of #3 (Hold).
The Medical - Instruments industry is part of the Medical sector. With its current Zacks Industry Rank of 94, this industry ranks in the top 39% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.